Clinical genitourinary cancer最新文献

Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial. 基线肾功能不全对匹氟司特 F-18 性能的影响以及匹氟司特 F-18 用药后肾功能变化的调查：OSPREY试验的结果。

Clinical genitourinary cancer Pub Date : 2024-09-13 DOI: 10.1016/j.clgc.2024.102223

Meera R Chappidi, Amir Iravani, Nancy Stambler, Saradha Baskaran, Vincent A DiPippo, Bela S Denes, Daniel W Lin

{"title":"Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial.","authors":"Meera R Chappidi, Amir Iravani, Nancy Stambler, Saradha Baskaran, Vincent A DiPippo, Bela S Denes, Daniel W Lin","doi":"10.1016/j.clgc.2024.102223","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.102223","url":null,"abstract":"Introduction: Piflufolastat F-18, a prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical, is predominantly eliminated via urinary excretion, and the kidneys have one of the highest absorbed doses. Therefore, this subgroup analysis aimed to investigate the impact of piflufolastat F-18 on renal function and its diagnostic performance in patients stratified by baseline renal function.Patients and methods: The OSPREY clinical trial enrolled 2 cohorts: A-high-risk patients undergoing radical prostatectomy with pelvic lymphadenectomy, and B-patients with suspected recurrent/metastatic prostate cancer on conventional imaging. Baseline estimated glomerular filtration rates were calculated, and patients were stratified by baseline chronic kidney disease (CKD) stage. Changes in serum creatinine within 28 days postdose and diagnostic performance of piflufolastat F-18 were assessed for each CKD stage group in both cohorts.Results: 385 patients (cohort A, n = 268; cohort B, n = 117) underwent piflufolastat F-18-PET/CT. Baseline and postpiflufolastat F-18 median creatinine levels (mg/dL) were similar for patients in cohort A (0.95 [n = 264] vs. 0.95 [n = 252], respectively) and cohort B (0.93 [n = 116] vs. 0.96 [n = 84], respectively). Among 332 men (cohort A, n = 249; cohort B, n = 83) with baseline and postpiflufolastat creatinine measurements, there were minimal changes in creatinine across all baseline CKD stage groups (median change ranged from -0.02 to 0.023 in groups with >1 patient). The diagnostic performance of piflufolastat F-18 showed no meaningful differences when stratified by baseline CKD stage.Conclusion: Piflufolastat F-18 appears to be safe and effective for imaging prostate cancer, including men with mild/moderate renal insufficiency.","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection. 原发性腹膜后淋巴结切除术病理阴性（pN0）患者的长期临床疗效。

Clinical genitourinary cancer Pub Date : 2024-09-03 DOI: 10.1016/j.clgc.2024.102217

Fady Baky, Nicole Liso, Brandon Williams, Andrea Knezevic, Samuel A Funt, Darren R Feldman, Brett Carver, Joel Sheinfeld, Richard S Matulewicz

{"title":"Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection.","authors":"Fady Baky, Nicole Liso, Brandon Williams, Andrea Knezevic, Samuel A Funt, Darren R Feldman, Brett Carver, Joel Sheinfeld, Richard S Matulewicz","doi":"10.1016/j.clgc.2024.102217","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.102217","url":null,"abstract":"Background: Patients who undergo primary retroperitoneal lymph node dissection (pRPLND) for early-stage testicular cancer and have no cancer (pN0) found in the retroperitoneum are believed to have an excellent prognosis. However, some experience relapse, potentially due to limitations of current staging methods. We aim to describe long-term outcomes and relapse patterns among a contemporary cohort of patients found to be pN0 at pRPLND to identify opportunities for improved diagnostic approaches and optimal patient selection.Methods: We reviewed our prospectively maintained database for patients who underwent pRPLND for nonseminomatous germ cell tumors at our tertiary cancer center during the period from January 1, 2000, through September 30, 2023 (n = 628). We excluded 282 patients with node-positive pathology for a final analytic cohort of 346 patients. Our primary outcome was recurrence-free survival (RFS). Secondary outcomes included timing and location of recurrence.Results: Of 346 included patients with pN0 pathology, 23 experienced relapse with a 2-year RFS rate of 93% (95% confidence interval: 90, 96). Most recurrences (70%) occurred in the lungs and within 6 months of pRPLND. Serum tumor markers were positive in 43% of patients at the time of relapse. All patients who relapsed were treated with salvage chemotherapy; 6 patients required additional surgical procedures. There was no testis cancer-related deaths.Conclusions: Two-year RFS for patients with pN0 pRPLND pathology is excellent. All recurrences were outside of the retroperitoneum, suggesting subclinical distant metastases at time of surgery and the benefits of a bilateral template dissection. Improved diagnostics may help better identify patients with disease within or outside of the retroperitoneum prior to pRPLND, helping guide treatment decisions.","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of a multidisciplinary tumour board (MTB) on treatment decision making for patients with renal cell carcinoma (RCC): 5-year data analysis 多学科肿瘤委员会（MTB）对肾细胞癌（RCC）患者治疗决策的影响：5 年数据分析

Clinical genitourinary cancer Pub Date : 2024-02-01 DOI: 10.1016/j.clgc.2024.01.021

L. Brink, A. Ruiter, B. Lagerveld, N. Graafland, A. Bex, H. Beerlage, R.J.M. van Moorselaar, P. Zondervan

引用次数: 0

The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study 根治性膀胱切除术在临床结节阳性膀胱癌中的作用：美国退伍军人健康管理局的一项研究

Clinical genitourinary cancer Pub Date : 2024-02-01 DOI: 10.1016/j.clgc.2024.02.006

Margaret Meagher, Kylie M. Morgan, Leah N. Deshler, Dhruv Puri, Kit Yuen, Aditya Bagrodia, Brent Rose, Tyler F Stewart, A. Salmasi

引用次数: 0

Treatment patterns and survival outcomes before and after access to immune checkpoint inhibitors for patients with metastatic urothelial carcinoma: A single-centre retrospective study from 2004 to 2021. 转移性尿路上皮癌患者使用免疫检查点抑制剂前后的治疗模式和生存结果：2004 年至 2021 年的一项单中心回顾性研究。

Clinical genitourinary cancer Pub Date : 2024-02-01 DOI: 10.1016/j.clgc.2024.01.019

Jose C. Tapia, Freya Bosma, J. Gavira, Sofia Sanchez, Maria Alejandra Molina, J. Sanz-Beltran, Cristina Martín-Lorente, G. Anguera, Pablo Maroto

引用次数: 0

Value of Cystatin C-Based Sarcopenia Index in Patients Undergoing Surgery for Renal Tumors 基于胱抑素 C 的骨质疏松指数在肾脏肿瘤手术患者中的价值

Clinical genitourinary cancer Pub Date : 2024-02-01 DOI: 10.1016/j.clgc.2024.02.002

S. Yajima, Y. Nakanishi, Ryo Andy Ogasawara, Naoki Imasato, Kohei Hirose, Sao Katsumura, M. Kataoka, H. Masuda

引用次数: 0

Clinical Profile and Outcomes of Carcinoma Penis patients receiving systemic therapy at an Indian tertiary care centre: A retrospective observational study 印度一家三级医疗中心接受系统治疗的阴茎癌患者的临床概况和疗效：回顾性观察研究

Clinical genitourinary cancer Pub Date : 2024-02-01 DOI: 10.1016/j.clgc.2024.02.004

V. Noronha, Venkatesh Kapu, Amit Joshi, N. Menon, Ajay Singh, G. Prakash, S. Menon, N. Sable, V. Murthy, M. Pal, Amandeepsingh Arora, Sravan Kumar, S. Banavali, K. Prabhash

引用次数: 0

Mainstream model of genetic testing for prostate cancer at a large tertiary cancer centre 大型三级癌症中心的前列腺癌基因检测主流模式

Clinical genitourinary cancer Pub Date : 2024-02-01 DOI: 10.1016/j.clgc.2024.02.003

Xin Wang, Larissa Waldman, Yael Silberman, Michael Wang, Caleb Tackey, Lilian Hanna, Danny Vesprini, Urban Emmenegger, Andrea Eisen, M. Smoragiewicz

引用次数: 0

Aquired cystic disease – associated renal cell carcinoma: a systematic review and meta-analysis 获得性囊肿病--相关肾细胞癌：系统回顾和荟萃分析

Clinical genitourinary cancer Pub Date : 2024-02-01 DOI: 10.1016/j.clgc.2024.02.001

N. X. Duong, Minh-Khang Le, Tuan Thanh Nguyen, Duy Duc Nguyen, H. Vuong, Tetsuo Kondo, Takahiko Mitsui

引用次数: 0

Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma 转移性尿路上皮癌中成纤维细胞生长因子受体基因改变的预后价值

Clinical genitourinary cancer Pub Date : 2024-02-01 DOI: 10.1016/j.clgc.2024.02.005

Sarah Fleming, Dina Gifkins, H. Resnick, Waleed Shalaby, Philip Rosenberg, Chris Gaj, Vittorio Maio, Albert Crawford, Grace Lu-Yao, Jianjun Gao, A. Siefker-Radtke

引用次数: 0